Outcomes |
Overall |
|
|
|
|
|
|
|
(n = 80) |
Overall |
|
|
|
|
|
|
|
(n = 80) |
ASTRALI group |
|
|
|
|
|
|
|
(n = 40) |
ASTRALI group |
|
|
|
|
|
|
|
(n = 40) |
ASTRALI group |
|
|
|
|
|
|
|
(n = 40) |
Control group |
|
|
|
|
|
|
|
(n = 40) |
Control group |
|
|
|
|
|
|
|
(n = 40) |
p value |
|
|
|
|
|
|
|
|
No. |
% |
No. |
No. |
% |
No. |
% |
|
CRP (T0) mg/L |
164 ± 67.787 |
164 ± 67.787 |
177 ± 79.931 |
177 ± 79.931 |
177 ± 79.931 |
151 ± 50.604 |
151 ± 50.604 |
0.082 |
CRP (T96) mg/L |
76 (50) |
76 (50) |
68 (55) |
68 (55) |
68
(55) |
89 (56) |
89 (56) |
0.033* |
IL-1β (T0) mg/L |
12.9 ± 5.091 |
12.9 ± 5.091 |
12.4 ± 4.835 |
12.4 ± 4.835 |
12.4 ±
4.835 |
13.5 ± 5.346 |
13.5 ± 5.346 |
0.364 |
IL-1β (T96) mg/L |
11.6 ± 5.408 |
11.6 ± 5.408 |
11.7 ± 5.338 |
11.7 ± 5.338 |
11.7 ± 5.338 |
11.4 ± 5.539 |
11.4 ± 5.539 |
0.796 |
IL-8 (T0) pg/mL |
40.0 ± 17.001 |
40.0 ± 17.001 |
38.1 ± 17.624 |
38.1 ± 17.624 |
38.1 ± 17.624 |
41.9 ± 16.349 |
41.9 ± 16.349 |
0.316 |
IL-8 (T96) pg/mL |
18.9 (23.9) |
18.9 (23.9) |
11.8 (7.3) |
11.8 (7.3) |
11.8 (7.3) |
35.5 (19.8) |
35.5 (19.8) |
<0.0001* |
IL-10 (T0) pg/mL |
15.1 ± 5.752 |
15.1 ± 5.752 |
14.1 ± 5.411 |
14.1 ± 5.411 |
14.1 ± 5.411 |
16.1 ± 5.967 |
16.1 ± 5.967 |
0.114 |
IL-10 (T96) pg/mL |
24.7 (17.3) |
24.7 (17.3) |
31.6 (25.8) |
31.6 (25.8) |
31.6 (25.8) |
17.7 (12.0) |
17.7 (12.0) |
<0.0001* |
SOD (T0) U/L |
8758 ± 4149 |
8758 ± 4149 |
8493 ± 4489 |
8493 ±
4489 |
8493 ± 4489 |
9023 ± 3819 |
9023 ± 3819 |
0.571 |
SOD (T96) U/L |
10272 (8621) |
10272 (8621) |
12876 (4627) |
12876 (4627) |
12876 (4627) |
5895 (6632) |
5895 (6632) |
<0.0001* |
MDA (T0) µM/L |
0.29 ±
0.055 |
0.29 ± 0.055 |
0.28 ± 0.0553 |
0.28 ± 0.0553 |
0.28 ± 0.0553 |
0.30 ± 0.0535 |
0.30 ± 0.0535 |
0.302 |
MDA (T96) µM/L |
0.211 (0.063) |
0.211 (0.063) |
0.197 (0.034) |
0.197 (0.034) |
0.197 (0.034) |
0.234 (0.074) |
0.234 (0.074) |
0.002* |
VC (T0) mg/L |
3.6 ±
0.988 |
3.6 ± 0.988 |
3.4 ± 1.021 |
3.4 ± 1.021 |
3.4 ± 1.021 |
3.9 ±
0.945 |
3.9 ± 0.945 |
0.300 |
VC (T48) mg/L |
22.2 ± 92.48 |
22.2 ± 92.48 |
94.9 ± 43.35 |
94.9 ± 43.35 |
94.9 ± 43.35 |
3.0 ± 1.30 |
3.0 ± 1.30 |
<0.0001* |
VC (T96) mg/L |
53.0 (126.40) |
53.0 (126.40) |
130.5 (111.65) |
130.5 (111.65) |
130.5 (111.65) |
4.2 (2.37) |
4.2 (2.37) |
<0.0001* |
VC (T120) mg/L |
19.3 (47.50) |
19.3 (47.50) |
50.4 (29.98) |
50.4 (29.98) |
50.4 (29.98) |
3.8 (0.62) |
3.8 (0.62) |
<0.0001* |
VC (T144) mg/L |
3.4 (0.95) |
3.4 (0.95) |
3.2 (1.95) |
3.2
(1.95) |
3.2 (1.95) |
3.5 (0.87) |
3.5 (0.87) |
0.739 |
P/F ratio (T0) |
161 (79) |
161 (79) |
157 (62) |
157 (62) |
157 (62) |
170 (102) |
170 (102) |
0.115 |
P/F ratio (T24) |
200 (83) |
200 (83) |
203 (79) |
203 (79) |
203 (79) |
191 (103) |
191 (103) |
0.073 |
P/F ratio (T48) |
229 (64) |
229 (64) |
233 (61) |
233 (61) |
233 (61) |
218 (70) |
218 (70) |
0.003* |
P/F ratio (T72) |
255 (84) |
255 (84) |
298 (67) |
298 (67) |
298 (67) |
233 (36) |
233 (36) |
<0.0001* |
P/F ratio (T96) |
289 (125) |
289 (125) |
342 (39) |
342 (39) |
342 (39) |
234 (57) |
234 (57) |
<0.0001* |
MV days |
5 (3) |
5 (3) |
4 (3) |
4 (3) |
4 (3) |
5 (3) |
5 (3) |
0.611 |
ICU days |
7 (6) |
7 (6) |
8 (6) |
8 (6) |
8 (6) |
7 (6) |
7
(6) |
0.649 |
VP days |
3 (5) |
3 (5) |
1 (4) |
1 (4) |
1 (4) |
4 (5) |
4 (5) |
0.019* |
7 days-mortality |
23 |
28.8 |
6 |
15 |
15 |
17 |
42.5 |
0.013* |
28 days-mortality |
33 |
41.3 |
13 |
32.5 |
32.5 |
20 |
50.0 |
0.173 |
Hypernatremia |
4 |
5.0 |
3 |
7.5 |
7.5 |
1 |
2.5 |
0.615 |
AKI |
9 |
11.3 |
4 |
10.0 |
10.0 |
5 |
12.5 |
1.000 |